Citalopram and cardiac toxicity

European Journal of Clinical Pharmacology

Volumn 69, Issue 4, 2013, Pages 755-760

  Cooke, M J ^a   Waring, W S ^a  

^a YORK TEACHING HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cardiac toxicity; Clinical toxicology; QT prolongation; Review; Selective serotonin reuptake inhibitor; Torsades de pointes

Indexed keywords

CITALOPRAM; DEXTROPROPOXYPHENE PLUS PARACETAMOL; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NEFAZODONE; NORCITALOPRAM; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADVERSE DRUG REACTION; BRADYCARDIA; CARDIOTOXICITY; CASE STUDY; CLINICAL PRACTICE; CLINICAL STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG OVERDOSE; DRUG SURVEILLANCE PROGRAM; DRUG USE; DRUG WITHDRAWAL; ECG ABNORMALITY; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DISEASE; HEART FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART PALPITATION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; ISCHEMIC HEART DISEASE; LONG QT SYNDROME 3; METABOLIC DISORDER; MYOCARDIAL DISEASE; NONHUMAN; PERICARDIAL DISEASE; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK FACTOR; TACHYCARDIA; TONIC CLONIC SEIZURE; TORSADE DES POINTES; VALVULAR HEART DISEASE;

ANIMALS; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART DISEASES; HUMANS; LONG QT SYNDROME; SEROTONIN UPTAKE INHIBITORS;

EID: 84876721757     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1408-1     Document Type: Review

References (40)

1. US Food and Drug Administration (2012) Abnormal heart rhythms associated with high doses of celexa (citalopram hydrobromide). Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm269481.htm (accessed 12/06/2012)
2. US Food and Drug Administration (2012) Celexa (citalopram hydrobromide) drug safety communication: revised recommendations, potential risk of abnormal heart rhythms. Available from: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm297624.htm (accessed 12/06/2012)
3. Medicines and Healthcare products Regulatory Agency (2011) Citalopram and escitalopram: QT interval prolongation: new maximum daily dose restrictions (including in elderly patients), contraindications, and warnings information. Available from: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ CON137769 (accessed 12/06/2012)
4. Pollock BG (2001) Citalopram: a comprehensive review. Expert Opin Pharmacother 2:681-698
5. Le Bloc'h Y, Woggon B, Weissenrieder H, Brawand-Amey M, Spagnoli J, Eap CB, Baumann P (2003) Routine therapeutic drug monitoring in patients treated with 10-360 mg/day citalopram. Ther Drug Monit 25:600-608
6. Mitcheson JS (2003) Drug binding to HERG channels: evidence for a "non-aromatic" binding site for fluvoxamine. Br J Pharmacol 139:883-884
7. Witchel HJ, Pabbathi VK, Hofmann G, Paul AA, Hancox JC (2002) Inhibitory actions of the selective serontonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett 512:59-66
8. Fredricson Overø K (1982) Kinetics of citalopram in test animals; drug exposure in safety studies. Prog Neuropsychopharmacol Biol Psychiatry 6:297-309
9. Boeck V, Overø KF, Svendsen O (1982) Studies on acute toxicity and drug levels of citalopram in the dog. Acta Pharmacol Toxicol 50:169-174
10. Muldoon C (1996) The safety and tolerability of citalopram. Int Clin Psychopharmacol 11(Suppl 1):35-40
11. Rasmussen SL, Overo KF, Tanghoj P (1999) Cardiac safety of citalopram: prospective trials and retrospective analyses. J Clin Psychopharmacol 19:407-415
12. Kanjanauthai S, Kanluen T, Chareonthaitawee P (2008) Citalopram induced torsades de pointes, a rare life threatening side effect. Int J Cardiol 131:e33-e34
13. Favre MP, Sztajzel J, Berschy G (1999) Bradycardia during citalopram treatment: a case report. Pharmacol Res 57:149-150
14. Deshmukh A, Ulveling K, Alla V, Abuissa H, Airey K (2012) Prolonged QTc interval and torsades de pointes induced by citalopram. Tex Heart Inst J 39:68-70
15. Tseng PT, Lee Y, Lin YE, Lin PY (2012) Low-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged woman: a case report and literature review. Gen Hosp Psychiatry 34:210
16. Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JR, Caverzasi E, Bonzano A, Piccinelli M, Barale F, De Ferrari GM (2005) QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry 4:1
17. Isbister GK, Prior FH, Foy A (2001) Citalopram-induced bradycardia and presyncope. Ann Pharmacother 35:1552-1555
18. Slavícek J, Paclt I, Hamplová J, Kittnar O, Trefný Z, Horácek BM (1998) Antidepressant drugs and heart electrical field. Physiol Res 47:297-300
19. Aström-Lilja C, Odeberg JM, Ekman E, Hägg S (2008) Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf 17:587-592
20. Medicines and Healthcare products Regulatory Agency (2012) Citalopram drug analysis print. Available from: http://www.mhra.gov.uk/home/groups/public/ documents/sentineldocuments/dap-1335337465722.pdf (accessed 12/06/2012)
21. Montgomery SA (1995) Selecting the optimum therapeutic dose of serotonin reuptake inhibitors: studies with citalopram. Int Clin Psychopharmacol 10(Suppl 1):23-27
22. Jimmink A, Caminada K, Hunfeld NG, Touw DJ (2008) Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs: overview of 26 cases. Ther Drug Monit 30:365-371
23. Catalano G, Catalano MC, Epstein MA, Tsambiras PE (2001) QTc interval prolongation associated with citalopram overdose: a case report literature review. Clin J Neuropharmacol 24:158-162
24. Tarabar AF, Hoffman RS, Lelson LS (2008) Citalopram overdose: late presentation if torsdae de pointes with cardiac arrest. J Med Toxicol 4:101-105
25. Grundemar L, Wohlfart B, Lagerstedt C, Bengtsson F, Eklundh G (1997) Symptoms and signs of severe citalopram overdose. Lancet 349:1602
26. Personne M, SjÖberg G, Persson H (1997) Citalopram overdose: review of cases treated in Swedish hospitals. J Toxicol Clin Toxicol 35:237-240
27. Rothenhäusler HB, Hoberl C, Ehrentrout S, Kapfhammer HP, Weber MM (2000) Suicide attempt by pure citalopram overdose causing long-lasting severe sinus bradycardia, hypotension and syncopes: successful therapy with a temporary pacemaker. Pharmacopsychiatry 33:150-152
28. Engebretsen KM, Harris CR, Wood JE (2003) Cardiotoxicity and late onset seizures with citalopram overdose. J Emerg Med 25:163-166
29. Chan CY, Waring WS (2007) Images in cardiovascular medicine. Tricyclic cardiotoxicity treated with sodium bicarbonate. Circulation 115:e63-e64
30. Liotier J, Coudoré F (2011) Drug monitoring of a case of citalopram overdosage. Drug Chem Toxicol 34:420-423
31. Masullo LN, Miller MA, Baker SD, Bose S, Levsky M (2006) Clinical course and toxicokinetic data following isolated citalopram overdose in an infant. Clin Toxicol 44:165-168
32. Kelly CA, Dhaun N, Laing WJ, Strachan FE, Good AM, Bateman DN (2004) Comparative toxicity of citalopram and the newer antidepressants after overdose. J Toxicol Clin Toxicol 42:67-71
33. Isbister GK, Bowe SJ, Dawson A, Whyte IM (2004) Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 42:277-285
34. Friberg LE, Isbister GK, Duffull SB (2006) Pharmacokinetic- pharmacodynamic modelling of QT interval prolongation following citalopram overdoses. Br J Clin Pharmacol 61:177-190
35. Waring WS, Graham A, Gray J, Wilson AD, Howell C, Bateman DN (2010) Evaluation of a QT nomogram for risk assessment after antidepressant overdose. Br J Clin Pharmacol 70:881-885
36. de Gregorio C, Morabito G, Cerrito M, Dattilo G, Oreto G (2011) Citalopram induced long QT syndrome and torsade de pointes: role for concomitant therapy and disease. Int J Cardiol 148:226-228
37. Priskorn M, Larsen F, Segonzac A, Moulin M (1997) Pharmacokinetic interaction study of citalopram and cimetidine in healthy subjects. Eur J Clin Pharmacol 52:241-242
38. Wall AJ, Bateman DN, Waring WS (2009) Variability in the quality of overdose advice in Summary of Product Characteristics (SPC) documents: gut decontamination recommendations for CNS drugs. Br J Clin Pharmacol 67:83-87
39. Waring WS, McGettigan P (2011) Clinical toxicology and drug regulation: a United Kingdom perspective. Clin Toxicol 49:452-456
40. Hawton K, Bergen H, Waters K, Murphy E, Cooper J, Kapur N (2011) Impact of withdrawal of the analgesic Co-proxamol on nonfatal self-poisoning in the UK. Crisis 32:81-87